Kristi Kennon, PA
Physician Assistant · Gulfport, MSNPI 1073923140
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 324 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 14.8% — the pattern of someone who eats at a lot of different presentations.
Across 324 payments — averaging $16.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$770
- Lilly USA, LLC$709
- AstraZeneca$614
- Pfizer$424
- GSK$280
- Takeda Pharmaceuticals U.S.A., Inc.$227
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,196100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 53 | $770 |
| Lilly USA, LLC | 46 | $709 |
| AstraZeneca | 33 | $614 |
| Pfizer | 26 | $424 |
| GSK | 25 | $280 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $227 |
| Novo Nordisk | 14 | $198 |
| Mylan Specialty L.p. | 9 | $180 |
| Amgen | 10 | $174 |
| Xeris Pharmaceuticals, Inc. | 8 | $155 |
| Lundbeck LLC | 8 | $146 |
| Sumitomo Pharma America, Inc. | 10 | $137 |
| Boehringer Ingelheim | 9 | $137 |
| Abbott | 6 | $111 |
| Astellas Pharma US Inc | 7 | $105 |
| Viatris Specialty LLC | 5 | $99 |
| Acerus Pharmaceuticals Corporation | 5 | $83 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $71 |
| Esperion Therapeutics, Inc. | 4 | $67 |
| Kowa Pharmaceuticals America, Inc. | 4 | $65 |
| Tolmar, Inc. | 4 | $63 |
| Jazz Pharmaceuticals Inc. | 3 | $56 |
| Vifor Pharma, Inc. | 2 | $47 |
| Exact Sciences | 2 | $40 |
| Antares Pharma, Inc. | 2 | $40 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $37 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Corcept Therapeutics | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 2 | $18 |
| Averitas Pharma Inc. | 1 | $18 |
| Merck | 1 | $17 |
| GRT US Holding, Inc. | 1 | $17 |
| Dexcom, Inc. | 1 | $13 |
| Vanda Pharmaceuticals Inc. | 1 | $13 |
How this compares
$5,196 in reported general payments places this provider in the 85th percentile of 278 physician assistant providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 89 | $106,201 |
| MounjaroTirzepatide | 87 | $100,932 |
| JardianceEmpagliflozin | 41 | $61,172 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 27 | $41,563 |
| RybelsusSemaglutide | 15 | $31,080 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 29 | $29,049 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $26,759 |
| EliquisApixaban | 25 | $25,910 |
| LinzessLinaclotide | 16 | $23,871 |
| Tresiba Flextouch U-200Insulin Degludec | 26 | $23,249 |
| MyrbetriqMirabegron | 16 | $22,203 |
| FarxigaDapagliflozin Propanediol | 27 | $20,239 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 18 | $18,223 |
| XareltoRivaroxaban | 11 | $16,706 |
| WegovySemaglutide | 11 | $14,429 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Wegovy | $198 | $151,709115 claims |
| Boehringer IngelheimJardiance, Trijardy Xr, Synjardy Xr | $137 | $120,95786 claims |
| Lilly USA, LLCMounjaro | $709 | $100,93287 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $614 | $49,28856 claims |
| GSKTrelegy Ellipta | $280 | $26,75930 claims |
| PfizerEliquis | $424 | $25,91025 claims |
| AbbVieLinzess, Synthroid | $770 | $25,19634 claims |
| Astellas Pharma US IncMyrbetriq | $105 | $22,20316 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $137 | $10,58915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 278 physician assistant providers in Mississippi.
Other physician assistant in Gulfport
- Bailey StokesGulfport$8K
- Amanda HarrisGulfport$6K
- Barbra DroddyGulfport$6K
- Anne SmitsGulfport$6K
- Kaitlyn McMackinGulfport$4K
- Thuy TranGulfport$4K
- Chessy MacdonaldGulfport$3K
- Lavinia DrambareanHattiesburg$382K
- Karmen ClarkOcean Springs$49K
- Kristen RichardsonFlowood$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.